LeonaBio (LONA) Accumulated Expenses (2019 - 2026)

LeonaBio (LONA) has 8 years of Accumulated Expenses data on file, last reported at $1.2 million in Q1 2026.

• Quarterly Accumulated Expenses fell 70.99% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 70.99% YoY) and the FY2025 annual result came in at $5.0 million, down 59.98% from the prior year.
• Accumulated Expenses retreated to $1.2 million in Q1 2026 per LONA's latest filing, from $5.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $17.0 million in Q3 2024 and bottomed at $1.2 million in Q1 2026.
• The 5-year median for Accumulated Expenses is $9.2 million (2022), against an average of $7.4 million.
• The widest annual swing landed in 2022, when Accumulated Expenses jumped 553.2%; it then slumped 87.8% in 2025.
• Tracing LONA's Accumulated Expenses over 5 years: stood at $10.0 million in 2022, then changed by 0.0% to $10.0 million in 2023, then climbed by 24.02% to $12.4 million in 2024, then plunged by 59.98% to $5.0 million in 2025, then tumbled by 75.46% to $1.2 million in 2026.
• Per Business Quant, the three latest LONA Accumulated Expenses figures stand at $1.2 million (Q1 2026), $5.0 million (Q4 2025), and $2.1 million (Q3 2025).

Peer Comparison